articleTop 1% cited
Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection
The Journal of Infectious Diseases · 2005 · Vol. 191(5) · pp. 654–665
The rgp120 HIV Vaccine Study Group✉(University of California Davis Medical Center)
Abstract
There was no overall protective effect. The efficacy trends in subgroups may provide clues for the development of effective immunization approaches.
HIV Research and TreatmentHerpesvirus Infections and TreatmentsHepatitis B Virus StudiesSeroconversionPlaceboMedicineVaccine trialRecombinant DNAInternal medicineHuman immunodeficiency virus (HIV)Clinical endpointLentivirusImmunology
MeSH terms
AdolescentAdultFemaleHumansMaleMiddle AgedRisk FactorsRisk-TakingTime FactorsVaccines, SyntheticHIV-1HIV InfectionsHIV Envelope Protein gp120AIDS VaccinesDisease Progression
Citations
931
FWCI
14.20
field-weighted impact
References
46
Percentile
100%
vs. same field & year
Citations per year
Cited by
Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand
The Journal of Infectious Diseases · 2006 · 825 citations
References
Risk of Human Immunodeficiency Virus Infection in Herpes Simplex Virus Type 2–Seropositive Persons: A Meta‐analysis
The Journal of Infectious Diseases · 2002 · 690 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.